Form 4: Xilio Therapeutics Director Yuan Xu Acquires 25,000 Stock Options

Director Yuan Xu of Xilio Therapeutics acquired 25,000 stock options at an exercise price of $1.02 on June 14, 2024, according to a recent SEC filing.

Summary

• On June 14, 2024, Yuan Xu, a director of Xilio Therapeutics, Inc., acquired 25,000 stock options.
• The exercise price for these options is $1.02 per share.
• The options vest on the earlier of June 14, 2025, or the date of the Issuer's next annual meeting of stockholders following the grant date, contingent upon continued service to the Issuer.
• The expiration date for the options is June 13, 2034.
• A Limited Power of Attorney was executed on June 12, 2024, granting Ren Russo, Christopher Frankenfield, Kevin Brennan, and Julia Walcott the authority to handle Section 16 reporting obligations on behalf of Yuan Xu.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction (stock option grant) without any explicit positive or negative implications.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year or until the next annual meeting is fairly typical.
• Comparable companies such as BioNTech, Moderna, and CRISPR Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates